Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Hunterian Medicine

Main focus: Gene editing for the treatment of genetic diseases

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: CRISPR-MAD7, other undisclosed

Funding stage: Private

Location: Cambridge, MA, USA

Website: https://www.hunterian.com/

Partners: Inscripta

Hunterian Medicine aims to enable CRISPR delivery within the limited AAV packaging capacity that currently represents one of the major challenges within therapeutic genome editing. The company is exploring a range of diseases and orphan indications for licensing and/or development, although it has yet to disclose targets and indications for its lead therapeutic programme.

Hunterian Medicine

Your Latest CMN News

CMN Weekly (26 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

Company: Hunterian Medicine

Search CRISPR Medicine